Department of Internal Medicine III, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
Chugai Pharma Europe Ltd., Frankfurt am Main, Germany.
Front Immunol. 2019 Jan 24;9:3129. doi: 10.3389/fimmu.2018.03129. eCollection 2018.
This paper aims to raise awareness of the different disease courses, comorbidities, and therapy situations in patients with giant cell arteritis (GCA), which require a differentiated approach and often a deviation from current treatment guidelines. With the approval of tocilizumab (TOC), which specifically binds to both soluble and membrane-bound IL-6 receptor and inhibits IL-6 receptor-mediated signaling, the spectrum of available effective treatment options has been significantly broadened. TOC yields an extensive range of possible applications that go beyond a glucocorticoid-saving effect. In this context, the treatment of GCA is dependent on the disease course as well as the associated comorbidities. The different stages of GCA in association to co-morbidities require a detailed treatment strategy.
本文旨在提高人们对巨细胞动脉炎（GCA）患者不同疾病进程、合并症和治疗情况的认识，这些患者需要采取差异化的治疗方法，而且往往需要偏离当前的治疗指南。托珠单抗（TOC）的获批，该药物特异性结合可溶性和膜结合型 IL-6 受体并抑制 IL-6 受体介导的信号转导，显著拓宽了有效的治疗选择范围。TOC 产生了广泛的可能应用，超出了糖皮质激素节约效应。在这种情况下，GCA 的治疗取决于疾病进程和相关的合并症。与合并症相关的 GCA 的不同阶段需要详细的治疗策略。
